ClinicalTrials.gg
CompletedNCT02713477Updated Jun 16, 2020

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010 and Insulin glargine HOE901 in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
165th of 178
20 · median 334
Started
2016
with 12 others
Phase 1
16 of 186
none open now
Registered
135th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 165th largest by enrollment of the 178 interventional ones that give a count, is one of 13 that started in 2016, is one of 16 in phase 1, and was the 135th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes mellitus (T2DM).

Secondary Objectives:

  • To assess the pharmacokinetics (PK) of lixisenatide following administration of 2 different doses of insulin glargine/lixisenatide fixed-ratio combination in Japanese patients with T2DM.
  • To assess the postprandial glucodynamic response to insulin glargine/lixisenatide fixed-ratio combination compared to insulin glargine alone in Japanese patients with T2DM.
  • To assess the safety and tolerability of insulin glargine/lixisenatide fixed-ratio combination in Japanese patients with T2DM.
Read the detailed description

The total study duration per patient will be approximately 6 to 13 weeks that will consist of a 2-28 days of screening period, a 3-day treatment period, a 7-14 days of washout period, and 1-day end of study visit.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the time of screening as established in the medical history.
  • Patients aged 20 to 75 years at screening.
  • ≤35 kg/m\^2 at screening.
  • Glycohemoglobin ≥7.0% and ≤10.0% at screening.
  • Fasting C-peptide ≥0.6 ng/mL at screening.

Exclusion criteria

Exclusion criteria:

  • Diabetes other than T2DM.
  • History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening.
  • History of hypoglycemia unawareness.
  • Hemoglobinopathy or hemolytic anemia.
  • History of myocardial infarction, stroke, or heart failure, history or presence of diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period.
  • History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.
  • Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment.
  • Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).
  • If female, pregnancy or breast-feeding.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Insulin glargine/ lixisenatide dose 1 Test 1

    Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition

    Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010

  • Experimental
    Insulin glargine/ lixisenatide dose 2 Test 2

    Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition

    Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010

  • Placebo comparator
    Placebo - Reference 1

    Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition

    Drug: Placebo

  • Other
    Insulin glargine (Lantus) - Reference 2

    Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition

    Drug: Insulin glargine HOE901

Interventions

  • DrugInsulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Lantus

  • DrugPlacebo

    Pharmaceutical form: solution Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Measurement of plasma glucose concentrations

    Time frame: 1 day (D1) in each treatment period

Secondary outcomes

  1. Measurement of serum insulin concentrations

    Time frame: 1 day (D1) in each treatment period

  2. Measurement of serum C-peptide concentrations

    Time frame: 1 day (D1) in each treatment period

  3. Measurement of plasma glucagon concentrations

    Time frame: 1 day (D1) in each treatment period

  4. Measurement of plasma lixisenatide concentrations

    Time frame: 1 day (D1) in each treatment period

  5. Number of patients with hypoglycemic events

    Time frame: Up to 2 weeks after each treatment

  6. Number of patients with adverse events

    Time frame: Up to 2 weeks after each treatment

  7. Measurement of anti-lixisenatide antibodies

    Time frame: 2 days (prior to first dosing and end of study visit)

  8. Measurement of anti-insulin antibodies

    Time frame: 2 days (prior to first dosing and end of study visit)

07

Study locations

1 site
  • Investigational Site Number 392001
    Fukuoka-Shi, Japan
08

References and documents

Publications

  • Inoue M, Lorenz M, Muto H, Wesch R, Hashimoto Y. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. Diabetes Obes Metab. 2019 Aug;21(8):2001-2005. doi: 10.1111/dom.13757. Epub 2019 May 24. PubMed 31050109 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 18, 2016
Start
Apr 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02713477
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 18, 2016
Start date
Apr 2016
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jun 16, 2020

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion